

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application No.	10/809,089	Art Unit:	4173
Applicant(s):	Andrew R. MARKS et al.	Examiner:	Benjamin J. Packard
Date Filed:	March 25, 2004	Conf. No.	7653
Docket No.	19240.596-US1	Cust. No.	56949
Title:	NOVEL ANTI-ARRHYTHMIC AND HEART FAILURE DRUGS THAT TARGET THE LEAK IN THE RYANODINE RECEPTOR (RYR2) AND USES THEREOF		

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**AMENDMENT AND REPLY UNDER 37 C.F.R. § 1.111**

In response to the Office Action dated November 27, 2007, Applicants submit the enclosed Amendment and Reply under 37 C.F.R. § 1.111 for entry in the above-identified application. Enclosed herewith are a Supplemental Information Disclosure Statement, a Form SB/08 disclosing the references, a copy of the references, four (4) new drawing sheets which contain Figures 15-18, and an Appendix B. Also enclosed is a petition for extension of time for three (3) months with the required fee, accordingly this response is being timely filed.

**Amendments to the Specification** begin on page 2.

**Amendments to the Claims** are reflected in the listing of claims which begins on page 5.

**Remarks** begin on page 11.